(Q29617585)
Statements
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis (English)
Wilhelm SM
Carter C
Tang L
Wilkie D
McNabola A
Rong H
Chen C
Zhang X
Vincent P
McHugh M
Cao Y
Shujath J
Gawlak S
Eveleigh D
Rowley B
Liu L
Adnane L
Lynch M
Auclair D
Taylor I
Gedrich R
Voznesensky A
Riedl B
Post LE
Bollag G
Trail PA
1 October 2004
64
19
7099-109